Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Table of Contents

January 2021; Volume 65,Issue 1

Perspective

  • Free
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
    Editor's Pick Perspective
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

    Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae. Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir...

    Muneerah M. Aleissa, Emily A. Silverman, Luisa M. Paredes Acosta, Cameron T. Nutt, Aaron Richterman, Francisco M. Marty

Meeting Review

  • FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development
    Editor's Pick Meeting Review
    FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development

    The U.S. Food and Drug Administration (FDA) hosted a public workshop entitled “Advancing Animal Models for Antibacterial Drug Development” on 5 March 2020. The workshop mainly focused on models of pneumonia caused by Pseudomonas aeruginosa and Acinetobacter baumannii. The program included...

    James M. Byrne, Ursula Waack, Edward A. Weinstein, Abhay Joshi, Simone M. Shurland, Dmitri Iarikov, Jürgen B. Bulitta, Binh An Diep, Tina Guina, William W. Hope, Matthew B. Lawrenz, Alexander J. Lepak, Brian M. Luna, Lynn Miesel, Andrew J. Phipps, Thomas J. Walsh, William Weiss, Thushi Amini, John J. Farley

Challenging Clinical Case in Antimicrobial Resistance

  • Free
    Imipenem plus Fosfomycin as Salvage Therapy for Vertebral Osteomyelitis
    Editor's Pick Challenging Clinical Case in Antimicrobial Resistance
    Imipenem plus Fosfomycin as Salvage Therapy for Vertebral Osteomyelitis

    We applied combination antibiotic therapy to treat vertebral osteomyelitis and a psoas abscess caused by glycopeptide-intermediate (MIC, 2 μg/ml) and daptomycin-nonsusceptible (>2 μg/ml) methicillin-resistant Staphylococcus aureus. The Etest synergy test showed the largest synergistic effects for imipenem/cilastatin and fosfomycin. Whole-gene sequencing showed...

    Itaru Nakamura, Tetsuo Yamaguchi, Kotaro Aoki, Yuri Miura, Satoko Sato, Hiroaki Fujita, Hidehiro Watanabe
  • Free
    Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant <em>Staphylococcus aureus</em> Infection: a Novel Combination Therapy
    Editor's Pick Challenging Clinical Case in Antimicrobial Resistance
    Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy

    Given that it is unlikely that randomized clinical trials will yield answers for treating the most challenging bacteremic infections caused by methicillin-resistant Staphylococcus aureus, clinicians, microbiologists, and pharmacists will have to cooperate to discover novel ways to select successful individualized antimicrobial therapy for these patients. An example of...

    George Sakoulas

Chemistry; Biosynthesis

  • New Amides Containing Selenium as Potent Leishmanicidal Agents Targeting Trypanothione Reductase
    Chemistry; Biosynthesis
    New Amides Containing Selenium as Potent Leishmanicidal Agents Targeting Trypanothione Reductase

    Two new series of 28 selenocyanate and diselenide derivatives containing amide moieties were designed, synthesized, and evaluated for their leishmanicidal activity against Leishmania infantum axenic amastigotes, and selectivity was assessed in human THP-1 cells. Eleven compounds exhibited excellent leishmanicidal activity with EC50 values lower than the...

    Mikel Etxebeste-Mitxeltorena, Daniel Plano, Socorro Espuelas, Esther Moreno, Carlos Aydillo, Antonio Jiménez-Ruiz, Juan Carlos García Soriano, Carmen Sanmartín
  • Regioisomerization of Antimalarial Drug WR99210 Explains the Inactivity of a Commercial Stock
    Chemistry; Biosynthesis
    Regioisomerization of Antimalarial Drug WR99210 Explains the Inactivity of a Commercial Stock

    WR99210, a former antimalarial drug candidate now widely used for the selection of Plasmodium transfectants, selectively targets the parasite’s dihydrofolate reductase thymidine synthase bifunctional enzyme (DHFR-TS) but not human DHFR, which is not fused with TS. Accordingly, WR99210 and plasmids expressing the human dhfr gene have become valued tools for the genetic modification of parasites in the laboratory....

    T. Parks Remcho, Sravanthi D. Guggilapu, Phillip Cruz, Glenn A. Nardone, Gavin Heffernan, Robert D. O’Connor, Carole A. Bewley, Thomas E. Wellems, Kristin D. Lane

Mechanisms of Action: Physiological Effects

  • Inhibition of PfMYST Histone Acetyltransferase Activity Blocks <span class="named-content genus-species" id="named-content-1">Plasmodium falciparum</span> Growth and Survival
    Mechanisms of Action: Physiological Effects
    Inhibition of PfMYST Histone Acetyltransferase Activity Blocks Plasmodium falciparum Growth and Survival

    One of the major barriers in the prevention and control of malaria programs worldwide is the growing emergence of multidrug resistance in Plasmodium parasites, and this necessitates continued efforts to discover and develop effective drug molecules targeting novel proteins essential for parasite survival. In recent years, epigenetic regulators have evolved as an attractive drug target option owing to their crucial role in...

    Utsav Sen, Akshaykumar Nayak, Juhi Khurana, Deepu Sharma, Ashish Gupta
  • Open Access
    Comparison of Proteomic Responses as Global Approach to Antibiotic Mechanism of Action Elucidation
    Mechanisms of Action: Physiological Effects
    Comparison of Proteomic Responses as Global Approach to Antibiotic Mechanism of Action Elucidation

    New antibiotics are urgently needed to address the mounting resistance challenge. In early drug discovery, one of the bottlenecks is the elucidation of targets and mechanisms. To accelerate antibiotic research, we provide a proteomic approach for the rapid classification of compounds into those with precedented and unprecedented modes of action. We established a proteomic response library of...

    Christoph H. R. Senges, Jennifer J. Stepanek, Michaela Wenzel, Nadja Raatschen, Ümran Ay, Yvonne Märtens, Pascal Prochnow, Melissa Vázquez Hernández, Abdulkadir Yayci, Britta Schubert, Niklas B. M. Janzing, Helen L. Warmuth, Martin Kozik, Jens Bongard, John N. Alumasa, Bauke Albada, Maya Penkova, Tadeja Lukežič, Nohemy A. Sorto, Nicole Lorenz, Reece G. Miller, Bingyao Zhu, Martin Benda, Jörg Stülke, Sina Schäkermann, Lars I. Leichert, Kathi Scheinpflug, Heike Brötz-Oesterhelt, Christian Hertweck, Jared T. Shaw, Hrvoje Petković, Jean M. Brunel, Kenneth C. Keiler, Nils Metzler-Nolte, Julia E. Bandow
  • Lack of Specificity of Phenotypic Screens for Inhibitors of the <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span> FAS-II System
    Mechanisms of Action: Physiological Effects
    Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System

    Phenotypic screening of inhibitors of the essential Mycobacterium tuberculosis FAS-II dehydratase HadAB led to the identification of GSK3011724A, a compound previously reported to inhibit the condensation step of FAS-II. Whole-cell-based and cell-free assays confirmed the lack of activity of GSK3011724A against the dehydratase despite evidence of cross-resistance...

    Anna E. Grzegorzewicz, Joël Lelièvre, Jorge Esquivias, Bhanupriya Angala, Jiuyu Liu, Richard E. Lee, Michael R. McNeil, Mary Jackson

Mechanisms of Resistance

  • <em>ERG11</em> Polymorphism in Voriconazole-Resistant <span class="named-content genus-species" id="named-content-1">Candida tropicalis</span>: Weak Role of <em>ERG11</em> Expression, Ergosterol Content, and Membrane Permeability
    Mechanisms of Resistance
    ERG11 Polymorphism in Voriconazole-Resistant Candida tropicalis: Weak Role of ERG11 Expression, Ergosterol Content, and Membrane Permeability

    Mutations in ERG11 were detected by gene sequencing and amino acid alignment in 18 Candida tropicalis strains with different degrees of sensitivity to voriconazole (VRC). ERG11 expression, sterol content, and membrane permeability were also evaluated. We report three missense mutations in ERG11 that resulted in resistance to VRC. The...

    Patricia Navarro-Rodríguez, Loida López-Fernández, Adela Martin-Vicente, Josep Guarro, Javier Capilla
  • Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span>
    Mechanisms of Resistance
    Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in Mycobacterium tuberculosis

    Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis. The activated drug hinders cell wall biosynthesis by inhibiting the InhA protein. INH-resistant strains of M. tuberculosis...

    K. B. Arun, Aravind Madhavan, Billu Abraham, M. Balaji, K. C. Sivakumar, P. Nisha, R. Ajay Kumar
  • Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Clinical Isolates from Canadian Hospitals
    Mechanisms of Resistance
    Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian Hospitals

    Here, we characterize the fosA genes from three Escherichia coli clinical isolates recovered from Canadian patients. Each fosA sequence was individually overexpressed in E. coli BW25113, and antimicrobial susceptibility testing was performed to assess their role in fosfomycin...

    Kieran A. Milner, Denice C. Bay, David Alexander, Andrew Walkty, James A. Karlowsky, Michael R. Mulvey, Meenu K. Sharma, George G. Zhanel
  • Open Access
    Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure
    Mechanisms of Resistance
    Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure

    Resistance to artemisinin-based combination therapy (ACT) in the Plasmodium falciparum parasite is threatening to reverse recent gains in reducing global deaths from malaria. While resistance manifests as delayed parasite clearance in patients, the phenotype can only spread geographically via the sexual stages and mosquito transmission. In addition to their asexual...

    Kathrin Witmer, Farah A. Dahalan, Michael J. Delves, Sabrina Yahiya, Oliver J. Watson, Ursula Straschil, Darunee Chiwcharoen, Boodtee Sornboon, Sasithon Pukrittayakamee, Richard D. Pearson, Virginia M. Howick, Mara K. N. Lawniczak, Nicholas J. White, Arjen M. Dondorp, Lucy C. Okell, Kesinee Chotivanich, Andrea Ruecker, Jake Baum
  • <em>De Novo</em> Resistance to Arg<sub>10</sub>-Teixobactin Occurs Slowly and Is Costly
    Mechanisms of Resistance
    De Novo Resistance to Arg10-Teixobactin Occurs Slowly and Is Costly

    Bacterial pathogens are rapidly evolving resistance to all clinically available antibiotics. One part of the solution to this complex issue is to better understand the resistance mechanisms to new and existing antibiotics. Here, we focus on two antibiotics. Teixobactin is a recently discovered promising antibiotic that is claimed to “kill pathogens without detectable resistance” (L. L. Ling, T. Schneider, A. J. Peoples, A. L. Spoering,...

    Daniel G. Lloyd, Benjamin J. Schofield, Matthew R. Goddard, Edward J. Taylor
  • Open Access
    Expression of the MexXY Aminoglycoside Efflux Pump and Presence of an Aminoglycoside-Modifying Enzyme in Clinical <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> Isolates Are Highly Correlated
    Mechanisms of Resistance
    Expression of the MexXY Aminoglycoside Efflux Pump and Presence of an Aminoglycoside-Modifying Enzyme in Clinical Pseudomonas aeruginosa Isolates Are Highly Correlated

    The impact of MexXY efflux pump expression on aminoglycoside resistance in clinical Pseudomonas aeruginosa isolates has been debated. In this study, we found that, in general, elevated mexXY gene expression levels in clinical P. aeruginosa isolates confer to slight increases in...

    Alexander Seupt, Monika Schniederjans, Jürgen Tomasch, Susanne Häussler
  • Open Access
    Systematic Investigation of Resistance Evolution to Common Antibiotics Reveals Conserved Collateral Responses across Common Human Pathogens
    Editor's Pick Mechanisms of Resistance
    Systematic Investigation of Resistance Evolution to Common Antibiotics Reveals Conserved Collateral Responses across Common Human Pathogens

    As drug resistance continues to grow, treatment strategies that turn resistance into a disadvantage for the organism will be increasingly relied upon to treat infections and to lower the rate of multidrug resistance. The majority of work in this area has investigated how resistance evolution toward a single antibiotic effects a specific organism’s collateral response to a wide variety of antibiotics. The results of these studies have...

    Mari C. Rodriguez de Evgrafov, Marius Faza, Konstantinos Asimakopoulos, Morten O. A. Sommer
  • Novel Mechanisms of Efflux-Mediated Levofloxacin Resistance and Reduced Amikacin Susceptibility in <span class="named-content genus-species" id="named-content-1">Stenotrophomonas maltophilia</span>
    Mechanisms of Resistance
    Novel Mechanisms of Efflux-Mediated Levofloxacin Resistance and Reduced Amikacin Susceptibility in Stenotrophomonas maltophilia

    Fluoroquinolone resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant factor is overproduction of efflux pumps, particularly SmeDEF, following mutation. Here, we report that mutations in the glycosyl transferase gene smlt0622 in S. maltophilia K279a mutant K...

    Punyawee Dulyayangkul, Karina Calvopiña, Kate J. Heesom, Matthew B. Avison
  • KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam
    Mechanisms of Resistance
    KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam

    This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla...

    Vincenzo Di Pilato, Noemi Aiezza, Valentina Viaggi, Alberto Antonelli, Luigi Principe, Tommaso Giani, Francesco Luzzaro, Gian Maria Rossolini
  • Experimental Evolution Identifies Adaptive Aneuploidy as a Mechanism of Fluconazole Resistance in <span class="named-content genus-species" id="named-content-1">Candida auris</span>
    Mechanisms of Resistance
    Experimental Evolution Identifies Adaptive Aneuploidy as a Mechanism of Fluconazole Resistance in Candida auris

    Candida auris is a newly emerging fungal pathogen of humans and has attracted considerable attention from both the clinical and basic research communities. Clinical isolates of C. auris are often resistant to one or more antifungal agents. To explore how antifungal resistance develops, we performed...

    Jian Bing, Tianren Hu, Qiushi Zheng, José F. Muñoz, Christina A. Cuomo, Guanghua Huang
  • Emergence of a Novel <em>tet</em>(L) Variant in <em>Campylobacter</em> spp. of Chicken Origin in China
    Mechanisms of Resistance
    Emergence of a Novel tet(L) Variant in Campylobacter spp. of Chicken Origin in China

    Tetracyclines are widely used in veterinary medicine and food animal production. Campylobacter members are major foodborne pathogens, and their resistance to tetracycline has been widely reported in different countries. To date, Tet(O), a ribosomal protection protein, is the only confirmed Tet resistance determinant in Campylobacter spp. Here, we reported the detection and characterization of a novel Tet resistance...

    Hong Yao, Dian Jiao, Wenbo Zhao, Aijuan Li, Ruichao Li, Xiang-Dang Du
  • Molecular Evaluation of Fluoroquinolone Resistance in Serial <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span> Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis
    Mechanisms of Resistance
    Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis

    Fluoroquinolones (FQ) are crucial components of multidrug-resistant tuberculosis (MDR TB) treatment. Differing levels of resistance are associated with specific mutations within the quinolone-resistance-determining region (QRDR) of gyrA. We sequenced the QRDR from serial isolates of MDR TB patients in the...

    Melisa Willby, Paige Chopra, Darrin Lemmer, Katherine Klein, Tracy L. Dalton, David M. Engelthaler, J. Peter Cegielski, James E. Posey
    and on behalf of Global PETTS Investigators
  • Open Access
    Secretion of and Self-Resistance to the Novel Fibupeptide Antimicrobial Lugdunin by Distinct ABC Transporters in <span class="named-content genus-species" id="named-content-1">Staphylococcus lugdunensis</span>
    Mechanisms of Resistance
    Secretion of and Self-Resistance to the Novel Fibupeptide Antimicrobial Lugdunin by Distinct ABC Transporters in Staphylococcus lugdunensis

    Lugdunin is the first reported nonribosomally synthesized antibiotic from human microbiomes. Its production by the commensal Staphylococcus lugdunensis eliminates the pathogen Staphylococcus aureus from human nasal microbiomes. The cycloheptapeptide lugdunin is the founding member of the new class...

    Sophia Krauss, Alexander Zipperer, Sebastian Wirtz, Julian Saur, Martin C. Konnerth, Simon Heilbronner, Benjamin O. Torres Salazar, Stephanie Grond, Bernhard Krismer, Andreas Peschel
  • Mutations in <em>fbiD</em> (<em>Rv2983</em>) as a Novel Determinant of Resistance to Pretomanid and Delamanid in <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span>
    Editor's Pick Mechanisms of Resistance
    Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis

    The nitroimidazole prodrugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis, but clinical evidence is limited to date. We selected pretomanid-resistant...

    Dalin Rifat, Si-Yang Li, Thomas Ioerger, Keshav Shah, Jean-Philippe Lanoix, Jin Lee, Ghader Bashiri, James Sacchettini, Eric Nuermberger
  • Evolution of Colistin Resistance in the <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics
    Mechanisms of Resistance
    Evolution of Colistin Resistance in the Klebsiella pneumoniae Complex Follows Multiple Evolutionary Trajectories with Variable Effects on Fitness and Virulence Characteristics

    The increasing prevalence of multidrug-resistant Klebsiella pneumoniae has led to a resurgence in the use of colistin as a last-resort drug. Colistin is a cationic antibiotic that selectively acts on Gram-negative bacteria through electrostatic interactions with anionic phosphate groups of the lipid A moiety of lipopolysaccharides (LPSs). Colistin resistance in...

    Axel B. Janssen, Dennis J. Doorduijn, Grant Mills, Malbert R. C. Rogers, Marc J. M. Bonten, Suzan H. M. Rooijakkers, Rob J. L. Willems, Jose A. Bengoechea, Willem van Schaik

Susceptibility

  • Open Access
    Tolerance of Gambian <span class="named-content genus-species" id="named-content-1">Plasmodium falciparum</span> to Dihydroartemisinin and Lumefantrine Detected by <em>Ex Vivo</em> Parasite Survival Rate Assay
    Susceptibility
    Tolerance of Gambian Plasmodium falciparum to Dihydroartemisinin and Lumefantrine Detected by Ex Vivo Parasite Survival Rate Assay

    Monitoring of Plasmodium falciparum sensitivity to antimalarial drugs in Africa is vital for malaria elimination. However, the commonly used ex vivo/in vitro 50% inhibitory concentration (IC50) test gives inconsistent results for several antimalarials, while the alternative ring-stage survival assay (RSA) for artemisinin derivatives has...

    Haddijatou Mbye, Fatoumata Bojang, Aminata Seedy Jawara, Bekai Njie, Nuredin Ibrahim Mohammed, Joseph Okebe, Umberto D’Alessandro, Alfred Amambua-Ngwa
  • <em>In Vitro</em> Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of <em>Enterobacteriaceae</em>, Including Molecularly Characterized Strains
    Susceptibility
    In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae, Including Molecularly Characterized Strains

    The activities of azithromycin, fusidic acid, vancomycin, doxycycline, and minocycline were evaluated alone and in combination with SPR741. A total of 202 Escherichia coli and 221 Klebsiella pneumoniae isolates were selected, and they included a genome-sequenced subset (n = 267), which was...

    Rodrigo E. Mendes, Paul R. Rhomberg, Troy Lister, Nicole Cotroneo, Thomas R. Parr, Mariana Castanheira
  • Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity
    Susceptibility
    Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity

    Olorofim is a novel antifungal drug in phase 2 trials. It has shown promising in vitro activity against various molds, except for Mucorales. Initially, we observed a broad range of EUCAST MICs for Aspergillus fumigatus. Here, we explored the MIC variability in more detail and prospectively investigated the susceptibility of contemporary clinical mold isolates...

    Karen Marie Thyssen Astvad, Karin Meinike Jørgensen, Rasmus Krøger Hare, Raluca Datcu, Maiken Cavling Arendrup
  • Azole and Amphotericin B MIC Values against <em>Aspergillus fumigatus</em>: High Agreement between Spectrophotometric and Visual Readings Using the EUCAST EDef 9.3.2 Procedure
    Susceptibility
    Azole and Amphotericin B MIC Values against Aspergillus fumigatus: High Agreement between Spectrophotometric and Visual Readings Using the EUCAST EDef 9.3.2 Procedure

    The EUCAST EDef 9.3.2 procedure recommends visual readings of azole and amphotericin B MICs against Aspergillus spp. Visual determination of MICs may be challenging. In this work, we aim to obtain and compare visual and spectrophotometric MIC readings of azoles and amphotericin B against Aspergillus fumigatus sensu lato isolates. A total of 847...

    Julia Serrano-Lobo, Ana Gómez, Waldo Sánchez-Yebra, Miguel Fajardo, Belén Lorenzo, Ferrán Sánchez-Reus, Inmaculada Vidal, Marina Fernández-Torres, Isabel Sánchez-Romero, Carlos Ruiz de Alegría-Puig, José Luis del Pozo, Patricia Muñoz, Pilar Escribano, Jesús Guinea
    and on behalf of the ASPEIN Study Group
  • <em>In Vitro</em> Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of <em>Enterobacterales</em>, <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span>, and <span class="named-content genus-species" id="named-content-2">Acinetobacter baumannii</span>: Results from China Antimicrobial Surveillance Network (CHINET) in 2018
    Susceptibility
    In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018

    This study evaluated the in vitro activity of cefepime-zidebactam in comparison with that of ceftazidime-avibactam and other comparators against clinically significant Gram-negative bacillus isolates. A total of 3,400 nonduplicate Gram-negative clinical isolates were collected from 45 medical centers across China in the CHINET Program in 2018, including Enterobacterales (n = 2,228),...

    Yang Yang, Yan Guo, Dandan Yin, Yonggui Zheng, Shi Wu, Demei Zhu, Fupin Hu
    and on behalf of the China Antimicrobial Surveillance Network (CHINET) Study Group

Analytical Procedures

  • Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation
    Analytical Procedures
    Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation

    The pharmacological activity of ceftriaxone depends on the unbound concentration. However, direct measurement of unbound concentrations is obstructive, and high individual variability of the unbound fraction of ceftriaxone was shown in children. We aim to evaluate and validate a method to predict unbound ceftriaxone concentrations in pediatric patients. Ninety-five pairs of concentrations (total and unbound) from 92 patients were...

    Min Kan, Hai-Yan Shi, Bing Han, Yue-E Wu, Qian Li, Zi-Xuan Guo, Xue Li, Guo-Xiang Hao, Yi Zheng, Le-Qun Su, Xin Huang, Zhong-Guo Sui, Wei Zhao

Antiviral Agents

  • The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA
    Antiviral Agents
    The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA

    Hepatitis B virus (HBV) mRNA metabolism is dependent upon host proteins PAPD5 and PAPD7 (PAPD5/7). PAPD5/7 are cellular, noncanonical, poly(A) polymerases (PAPs) whose main function is to oligoadenylate the 3′ end of noncoding RNA (ncRNA) for exosome degradation. HBV seems to exploit these two ncRNA quality-control factors for viral mRNA stabilization, rather than degradation. RG7834 is a small-molecule compound that binds PAPD5/7 and...

    Liren Sun, Fang Zhang, Fang Guo, Fei Liu, Jessie Kulsuptrakul, Andreas Puschnik, Min Gao, Rene Rijnbrand, Michael Sofia, Timothy Block, Tianlun Zhou
  • Effect of a Neuropilin-1-Derived Virus Receptor Trap on Enterovirus A71 Infection <em>In Vitro</em>
    Antiviral Agents
    Effect of a Neuropilin-1-Derived Virus Receptor Trap on Enterovirus A71 Infection In Vitro

    We discovered that neuropilin 1 (NRP1) is a new receptor candidate to mediate enterovirus A71 (EVA71) into cells. In the engineered form as a decoy receptor, NRP1 was able to recognize and neutralize EVA71 but not enterovirus D68 or coxsackievirus B3 (CVB3). NRP1 recognizes EVA71 through a novel domain on the VP3 capsid protein. The principle in the design, engineering, and refinement of the NRP1-based decoy receptor described in this...

    Hsiang-Ching Wang, Peng-Nien Huang, Hui-Chen Hung, Sung-Nien Tseng, Chia-Chia Chang, Ya-Ru Tsai, Yun-Ming Wang, Shin-Ru Shih, John Tsu-An Hsu
  • Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants
    Antiviral Agents
    Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants

    Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in early childhood. However, no vaccines have yet been approved for prevention of RSV infection, and the treatment options are limited. Therefore, development of effective and safe anti-RSV drugs is needed. In this study, we evaluated the antiviral activity and mechanism of action of a novel macrocyclic anti-RSV compound, TP0591816. TP0591816...

    Ippei Yoshida, Kaho Arikawa, Yusuke Honma, Shoko Inatani, Mitsukane Yoshinaga, Hiroyuki Sugiyama
  • Free
    Development of a Simple <em>In Vitro</em> Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase
    Antiviral Agents
    Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase

    Nucleotide analogs targeting viral RNA polymerase have been proved to be an effective strategy for antiviral treatment and are promising antiviral drugs to combat the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. In this study, we developed a robust in vitro nonradioactive primer extension assay to quantitatively evaluate the efficiency of incorporation of nucleotide analogs by SARS-CoV-2 RNA-...

    Gaofei Lu, Xi Zhang, Weinan Zheng, Jialei Sun, Lan Hua, Lan Xu, Xin-jie Chu, Sheng Ding, Wen Xiong
  • Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy
    Antiviral Agents
    Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy

    Congenital cytomegalovirus (HCMV) infection may cause significant fetal malformation, lifelong disease, and, in severe cases, fetal or neonatal death. Placental infection with HCMV is the major mechanism of mother-to-child transmission (MTCT) and fetal injury. Thus, any pharmaceutical antiviral interference to reduce viral load may reduce placental damage, MTCT, and fetal disease. However, there is currently no licensed HCMV antiviral...

    Stuart T. Hamilton, Manfred Marschall, William D. Rawlinson
  • Free
    Repurposing Nucleoside Analogs for Human Coronaviruses
    Antiviral Agents
    Repurposing Nucleoside Analogs for Human Coronaviruses

    Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated...

    Keivan Zandi, Franck Amblard, Katie Musall, Jessica Downs-Bowen, Ruby Kleinbard, Adrian Oo, Dongdong Cao, Bo Liang, Olivia O. Russell, Tamara McBrayer, Leda Bassit, Baek Kim, Raymond F. Schinazi
  • Open Access
    <em>In Vitro</em> Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles
    Antiviral Agents
    In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles

    The use of antiretroviral therapy (ART) as preexposure prophylaxis (PrEP) is an effective strategy for preventing HIV acquisition. The cellular consequences of PrEP exposure, however, have not been sufficiently explored to determine potential effects on health in individuals without HIV. In this study, peripheral blood mononuclear cells (PBMCs) from people without HIV were exposed to tenofovir disoproxil fumarate (TDF) or emtricitabine...

    Emily R. Bowman, Cheryl Cameron, Brian Richardson, Manjusha Kulkarni, Janelle Gabriel, Aaren Kettelhut, Lane Hornsby, Jesse J. Kwiek, Abigail Norris Turner, Carlos Malvestutto, Jose Bazan, Susan L. Koletar, Susanne Doblecki-Lewis, Michael M. Lederman, Mark Cameron, Nichole R. Klatt, Jordan E. Lake, Nicholas T. Funderburg
  • Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1
    Antiviral Agents
    Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1

    During infection with the human immunodeficiency virus type 1 (HIV-1), latent reservoirs are established that circumvent full eradication of the virus by antiretroviral therapy (ART) and are the source for viral rebound after cessation of therapy. As these reservoirs are phenotypically indistinguishable from infected cells, current strategies aim to reactivate these reservoirs, followed by pharmaceutical and immunological destruction of...

    Ariane Zutz, Lin Chen, Franziska Sippl, Andreas Humpe, Christian Schölz
  • Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders
    Antiviral Agents
    Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

    Four pre-exposure prophylaxis (PrEP) users with gastrointestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease, or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite self-reported high adherence, trough plasma tenofovir concentrations (after supervised intake) were significantly lower in these patients than in PrEP recipients without gastrointestinal...

    Andrea Calcagno, Ivano Dal Conte, Dario Cattaneo, Roberto Testi, Massimiliano Mistrangelo, Cristina Gervasoni, Amedeo de Nicolò, Stefano Bonora, Antonio D’Avolio, Giovanni Di Perri

Epidemiology and Surveillance

  • Carbapenemase-Producing Gram-Negative Bacteria from American Crows in the United States
    Epidemiology and Surveillance
    Carbapenemase-Producing Gram-Negative Bacteria from American Crows in the United States

    Wild corvids were examined for the presence of carbapenemase-producing Gram-negative bacteria in the United States. A total of 13 isolates were detected among 590 fecal samples of American crow; 11 Providencia rettgeri isolates harboring blaIMP-27 on the chromosome as a class 2 integron gene cassette within the Tn7 transposon, 1...

    Iva Kutilova, Adam Valcek, Costas C. Papagiannitsis, Darina Cejkova, Martina Masarikova, Veronika Paskova, Lenka Davidova-Gerzova, Petra Videnska, Jaroslav Hrabak, Ivan Literak, Monika Dolejska
  • <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Sequence Type 457 Is an Emerging Extended-Spectrum-β-Lactam-Resistant Lineage with Reservoirs in Wildlife and Food-Producing Animals
    Epidemiology and Surveillance
    Escherichia coli Sequence Type 457 Is an Emerging Extended-Spectrum-β-Lactam-Resistant Lineage with Reservoirs in Wildlife and Food-Producing Animals

    Silver gulls carry phylogenetically diverse Escherichia coli, including globally dominant extraintestinal pathogenic E. coli (ExPEC) sequence types and pandemic ExPEC-ST131 clades; however, our large-scale study (504 samples) on silver gulls nesting off the coast of New South Wales identified...

    Kristina Nesporova, Ethan R. Wyrsch, Adam Valcek, Ibrahim Bitar, Khin Chaw, Patrick Harris, Jaroslav Hrabak, Ivan Literak, Steven P. Djordjevic, Monika Dolejska
  • Heterogeneity and Diversity of <em>mcr-8</em> Genetic Context in Chicken-Associated <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span>
    Epidemiology and Surveillance
    Heterogeneity and Diversity of mcr-8 Genetic Context in Chicken-Associated Klebsiella pneumoniae

    Increasing mobile colistin resistance, mediated by the mcr gene family, in Enterobacteriaceae has become a global concern. Among the 10 reported mcr genes, mcr-8 was first identified in Klebsiella pneumoniae, which could cause severe infections with high mortality. Information about the prevalence and genetic context of mcr-8...

    Beibei Wu, Yao Wang, Zhuoren Ling, Zhuoling Yu, Zhangqi Shen, Suxia Zhang, Xiaoming Wang

Experimental Therapeutics

  • Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant <span class="named-content genus-species" id="named-content-1">Candida auris</span>
    Experimental Therapeutics
    Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant Candida auris

    The limited therapeutic options and the recent emergence of multidrug-resistant Candida species present a significant challenge to human medicine and underscore the need for novel therapeutic approaches. Drug repurposing appears as a promising tool to augment the activity of current azole antifungals, especially against multidrug-resistant Candida auris. In...

    Hassan E. Eldesouky, Ehab A. Salama, Nadia A. Lanman, Tony R. Hazbun, Mohamed N. Seleem
  • Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Pneumonia
    Experimental Therapeutics
    Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia

    Current guidelines recommend vancomycin and linezolid as first-line agents against methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia. Telavancin is a potential new therapeutic alternative, specifically in monomicrobial MRSA pneumonia. This study compared the efficacies of telavancin versus linezolid in a porcine model of severe MRSA pneumonia. In...

    D. Battaglini, A. Motos, G. Li Bassi, H. Yang, F. Pagliara, M. Yang, E. Aguilera Xiol, A. Meli, J. Bobi, G. Frigola, T. Senussi, F. Idone, C. Travierso, C. Chiurazzi, L. Fernandez-Barat, M. Rigol, J. Ramirez, P. Pelosi, D. Chiumello, M. Antonelli, D. P. Nicolau, J. Bringue, A. Artigas, L. Guerrero, D. Soy, A. Torres
  • The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection
    Experimental Therapeutics
    The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection

    Invasive fungal diseases represent an unmet clinical need that could benefit from novel immunotherapeutic approaches. Host pattern recognition receptors (e.g., Toll-like receptors, C-type lectins, or scavenger receptors) that sense conserved fungal cell wall constituents may provide suitable immunotherapeutic antifungal agents. Thus, we explored the therapeutic potential of the lymphocyte class I scavenger receptor CD5, a nonredundant...

    María Velasco-de Andrés, Cristina Català, Sergi Casadó-Llombart, Mario Martínez-Florensa, Inês Simões, Joaquín García-Luna, Gustavo Mourglia-Ettlin, Óscar Zaragoza, Esther Carreras, Francisco Lozano
  • Activity of Tigecycline or Colistin in Combination with Zidovudine against <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Harboring <em>tet</em>(X) and <em>mcr-1</em>
    Experimental Therapeutics
    Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet(X) and mcr-1

    Alternative therapeutic options are urgently needed against multidrug-resistant Escherichia coli infections, especially in situations of preexisting tigecycline and colistin resistance. Here, we investigated synergistic activity of the antiretroviral drug zidovudine in combination with tigecycline or colistin against...

    Yu-Feng Zhou, Ping Liu, Shu-He Dai, Jian Sun, Ya-Hong Liu, Xiao-Ping Liao
  • Optimization of a Noncanonical Anti-infective: Interrogation of the Target Binding Pocket for a Small-Molecule Inhibitor of <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Polysaccharide Capsule Expression
    Editor's Pick Experimental Therapeutics
    Optimization of a Noncanonical Anti-infective: Interrogation of the Target Binding Pocket for a Small-Molecule Inhibitor of Escherichia coli Polysaccharide Capsule Expression

    We previously identified a small-molecule inhibitor of capsule biogenesis (designated DU011) and identified its target as MprA, a MarR family transcriptional repressor of multidrug efflux pumps. Unlike other proposed MprA ligands, such as salicylate and 2,4-dinitrophenol (DNP), DU011 does not alter Escherichia coli antibiotic resistance and has significantly enhanced...

    Mehreen Arshad, Grace A. Beggs, Richard G. Brennan, Patrick C. Seed
  • Open Access
    Small-Molecule Antibiotics Inhibiting tRNA-Regulated Gene Expression Is a Viable Strategy for Targeting Gram-Positive Bacteria
    Experimental Therapeutics
    Small-Molecule Antibiotics Inhibiting tRNA-Regulated Gene Expression Is a Viable Strategy for Targeting Gram-Positive Bacteria

    Bacterial infections and the rise of antibiotic resistance, especially multidrug resistance, have generated a clear need for discovery of novel therapeutics. We demonstrated that a small-molecule drug, PKZ18, targets the T-box mechanism and inhibits bacterial growth. The T-box is a structurally conserved riboswitch-like gene regulator in the 5′ untranslated region (UTR) of numerous essential genes of Gram-positive bacteria. T-boxes are...

    Ville Y. P. Väre, Ryan F. Schneider, Haein Kim, Erica Lasek-Nesselquist, Kathleen A. McDonough, Paul F. Agris
  • Open Access
    Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia <em>Ex Vivo</em>: Potentials and Pitfalls
    Experimental Therapeutics
    Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia Ex Vivo: Potentials and Pitfalls

    For a long while, 8-aminoquinoline compounds have been the only therapeutic agents against latent hepatic malaria parasites. These have poor activity against the blood-stage plasmodia causing acute malaria and must be used in conjunction with partner blood schizontocidal agents. We examined the impacts of one such agent, chloroquine, upon the activity of primaquine, an 8-aminoquinoline, against hepatic stages of...

    Laurent Dembélé, Jean-François Franetich, Valérie Soulard, Nadia Amanzougaghene, Shahin Tajeri, Teun Bousema, Geert-Jan van Gemert, Roger Le Grand, Nathalie Dereuddre-Bosquet, J. Kevin Baird, Dominique Mazier, Georges Snounou
  • Disparate Effects of Metformin on <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span> Infection in Diabetic and Nondiabetic Mice
    Experimental Therapeutics
    Disparate Effects of Metformin on Mycobacterium tuberculosis Infection in Diabetic and Nondiabetic Mice

    Comorbid type 2 diabetes poses a great challenge to the global control of tuberculosis. Here, we assessed the efficacy of metformin (MET), an antidiabetic drug, in mice infected with a very low dose of Mycobacterium tuberculosis. In contrast to diabetic mice, infected nondiabetic mice that received the same therapeutic concentration of MET presented with significantly...

    Harindra D. Sathkumara, Karyna Hansen, Socorro Miranda-Hernandez, Brenda Govan, Catherine M. Rush, Lars Henning, Natkunam Ketheesan, Andreas Kupz
  • Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice
    Experimental Therapeutics
    Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice

    Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different from antibiotics and the lack of understanding potentially limits optimal dosing. The aim of this study...

    Michael Y. T. Chow, Rachel Yoon Kyung Chang, Mengyu Li, Yuncheng Wang, Yu Lin, Sandra Morales, Andrew J. McLachlan, Elizabeth Kutter, Jian Li, Hak-Kim Chan
  • Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice
    Experimental Therapeutics
    Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice

    The mouse ascending urinary tract infection model was used to study the pharmacokinetic/pharmacodynamic (PKPD) relationships of the effect of ciprofloxacin in subcutaneous treatment for 3 days with varying doses and dosing intervals against a susceptible Escherichia coli strain (MIC, 0.032 mg/liter). Further, a humanized dose of ciprofloxacin was administered for 3...

    Lotte Jakobsen, Carina Vingsbro Lundberg, Niels Frimodt-Møller
  • Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an <em>In Vitro</em> Pharmacokinetic/Pharmacodynamic Model
    Experimental Therapeutics
    Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model

    This study aimed to test the efficacy of bacteriophage-antibiotic combinations (BACs) in vitro in 24-h time-kill settings and in ex vivo simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic models for 96 h. BACs prevented the development of bacteriophage resistance, while some bacteriophage resistance emerged in bacteriophage-alone treatments. In addition, BACs resulted in an enhancement of bacterial...

    Razieh Kebriaei, Katherine L. Lev, Kyle C. Stamper, Susan M. Lehman, Sandra Morales, Michael J. Rybak
  • Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for <span class="named-content genus-species" id="named-content-1">Enterococcus faecalis</span> Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?
    Experimental Therapeutics
    Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

    Ceftriaxone administered as once-daily high-dose short infusion combined with ampicillin has been proposed for the treatment of Enterococcus faecalis infective endocarditis in outpatient parenteral antibiotic therapy programs (OPAT). This combination requires synergistic activity, but the attainment of ceftriaxone synergic concentration (Cs) with the regimen proposed...

    Laura Herrera-Hidalgo, Arístides de Alarcón, Luis Eduardo López-Cortes, Rafael Luque-Márquez, Luis Fernando López-Cortes, Alicia Gutiérrez-Valencia, María Victoria Gil-Navarro
    and on behalf of Grupo para el Estudio de las Infecciones Cardiovasculares de la Sociedad Andaluza de Enfermedades Infecciosas

Clinical Therapeutics

  • Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa
    Clinical Therapeutics
    Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa

    Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) patients receiving ethambutol, cycloserine, or terizidone as part of a standardized regimen were compared, determining occurrence of serious adverse drug events (SADEs). Newly diagnosed adult MDR-TB patients were enrolled between 2000 and 2004, receiving a standardized multidrug regimen for 18 to 24 months, including ethambutol, cycloserine, or terizidone. Cycloserine...

    Martha L. van der Walt, Karen Shean, Piet Becker, Karen H. Keddy, Joey Lancaster
  • Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing <em>Enterobacterales</em>?: a Systematic Review and Meta-analysis
    Clinical Therapeutics
    Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis

    Carbapenem-sparing regimens are needed for the treatment of infections caused by extended-spectrum-β-lactamase (ESBL)- and AmpC-producing members of the Enterobacterales. We sought to compare the clinical efficacy of ceftazidime/avibactam and carbapenems against ESBL- and AmpC-producing Enterobacterales species. A systematic review and meta-analysis of randomized controlled trials comparing ceftazidime/avibactam with...

    Burcu Isler, Yukiko Ezure, Jose Luis García-Fogeda Romero, Patrick Harris, Adam G. Stewart, David L. Paterson
  • Open Access
    An Exposure-Response Perspective on the Clinical Dose of Pretomanid
    Clinical Therapeutics
    An Exposure-Response Perspective on the Clinical Dose of Pretomanid

    Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intolerant or nonresponsive multidrug-resistant tuberculosis. The recommended dose of pretomanid is 200 mg once daily with food. The objective of this work was to retrospectively evaluate this...

    Jerry R. Nedelman, David H. Salinger, Vishak Subramoney, Rob Woolson, Karen Wade, Mengchun Li, Daniel Everitt, Carl M. Mendel, Mel Spigelman
  • Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers
    Clinical Therapeutics
    Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers

    Continuous infusion (CON) of fosfomycin has been proposed as potentially advantageous in certain clinical scenarios. However, no clinical data on the pharmacokinetics (PK) of fosfomycin after CON are available to date. This study aimed to investigate the PK of fosfomycin after CON and compare it with intermittent infusion (INT) of fosfomycin. A randomized two-way crossover study including 8 healthy male volunteers was performed. Each...

    Valentin al Jalali, Peter Matzneller, Beatrix Wulkersdorfer, Scharon Chou, Soma Bahmany, Birgit C. P. Koch, Markus Zeitlinger
  • Optimization of an Assay To Determine Colonization Resistance to <span class="named-content genus-species" id="named-content-1">Clostridioides difficile</span> in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics
    Clinical Therapeutics
    Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics

    A healthy, intact gut microbiota is often resistant to colonization by gastrointestinal pathogens. During periods of dysbiosis, however, organisms such as Clostridioides difficile can thrive. We describe an optimized in vitro colonization resistance assay for C. difficile in stool (CRACS)...

    Hannah C. Harris, Emma L. Best, Charmaine Normington, Nathalie Saint-Lu, Frédérique Sablier-Gallis, Jean de Gunzburg, Antoine Andremont, Mark H. Wilcox, Caroline H. Chilton
  • Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients
    Clinical Therapeutics
    Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients

    The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in nonobese patients. It is unknown whether cysC can also improve vancomycin target trough attainment in overweight and obese patients. We conducted a retrospective observational study of overweight or obese hospitalized adults with stable renal function administered intravenous vancomycin between January...

    Hilary R. Teaford, Ryan W. Stevens, Andrew D. Rule, Kristin C. Mara, Kianoush B. Kashani, John C. Lieske, John O’Horo, Erin F. Barreto
  • Decreased Overall and Inappropriate Antibiotic Prescribing in a Veterans Affairs Hospital Emergency Department following a Peer Comparison-Based Stewardship Intervention
    Clinical Therapeutics
    Decreased Overall and Inappropriate Antibiotic Prescribing in a Veterans Affairs Hospital Emergency Department following a Peer Comparison-Based Stewardship Intervention

    Antibiotic prescribing is very common in emergency departments (EDs). Optimal stewardship intervention strategies in EDs are not well defined. We conducted a prospective, observational cohort study in a Veterans Affairs ED in which clinician education and monthly e-mail-based peer comparisons were directed against all oral antibiotic prescribing for discharged patients. Oral antibiotic prescriptions were compared in baseline (June 2016...

    Deanna J. Buehrle, Rameez H. Phulputo, Marilyn M. Wagener, Cornelius J. Clancy, Brooke K. Decker
  • Open Access
    Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain
    Clinical Therapeutics
    Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain

    The aim of this study was to describe the pharmacokinetics of ceftolozane-tazobactam in plasma and cerebrospinal fluid (CSF) of infected critically ill patients. In a prospective observational study, critically ill patients (≥18 years) with an indwelling external ventricular drain received a single intravenous dose of 3.0 g ceftolozane-tazobactam. Serial plasma and CSF samples were collected for measurement of unbound ceftolozane and...

    Fekade B. Sime, Melissa Lassig-Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L. Parker, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts
  • Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of <span class="named-content genus-species" id="named-content-1">Neisseria gonorrhoeae</span>
    Clinical Therapeutics
    Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae

    The threat of ceftriaxone-resistant Neisseria gonorrhoeae necessitates new gonorrhea treatment regimens. Repurposing older antibiotics not routinely used for N. gonorrhoeae may expeditiously identify new therapies. Ideally, all recommended therapies should eradicate gonorrhea at the pharynx. Between...

    Lindley A. Barbee, Olusegun O. Soge, Negusse Ocbamichael, Angela LeClair, Matthew R. Golden
  • Patients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study Enrollment
    Clinical Therapeutics
    Patients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study Enrollment

    Erythema migrans is the most common clinical manifestation of Lyme disease, with concomitant subjective symptoms occurring in ∼65% of cases in the United States. We evaluated the impact of having been started on antibiotic treatment before study enrollment on 12 particular symptoms for 38 subjects with erythema migrans versus 52 untreated subjects. There were no significant differences in the frequency of having at least one symptom or...

    Gary P. Wormser, Donna McKenna, Eliana Jacobson, Elayna M. Shanker, Keith D. Shaffer, Carol Scavarda, Paul Visintainer
  • A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges
    Clinical Therapeutics
    A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges

    Ventriculostomy-associated infections in critically ill patients remain therapeutically challenging because of drug- and disease-related factors that contribute to suboptimal antibiotic concentrations in cerebrospinal fluid. Optimal antibiotic dosing for the treatment and prevention of such infections should be based on robust and contextually specific pharmacokinetic data. The objects of this study were to describe and critically...

    Nilesh Kumta, Jason A. Roberts, Jeffrey Lipman, Wai Tat Wong, Gavin M. Joynt, Menino Osbert Cotta

Pharmacology

  • Open Access
    Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis
    Pharmacology
    Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis

    Optimal dosing of children with tuberculous meningitis (TBM) remains uncertain and is currently based on the treatment of pulmonary tuberculosis in adults. This study aimed to investigate the population pharmacokinetics of isoniazid, rifampin, pyrazinamide, and ethambutol in Vietnamese children with TBM, to propose optimal dosing in these patients, and to determine the relationship between drug exposure and treatment outcome. A total of...

    Navarat Panjasawatwong, Thanaporn Wattanakul, Richard M. Hoglund, Nguyen Duc Bang, Thomas Pouplin, Wichit Nosoongnoen, Vi Nguyen Ngo, Jeremy N. Day, Joel Tarning
  • Open Access
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
    Pharmacology
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

    A population pharmacokinetic (PopPK) model of delamanid in patients with pulmonary multidrug-resistant tuberculosis (MDR-TB) was developed using data from four delamanid clinical trials. The final PopPK data set contained 20,483 plasma samples from 744 patients with MDR-TB receiving an optimized background regimen (OBR). Delamanid PK was adequately described for all observed dosing regimens and subpopulations by a two-compartment model...

    Xiaofeng Wang, Suresh Mallikaarjun, Ekaterina Gibiansky
  • Open Access
    Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
    Pharmacology
    Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

    Pharmacokinetic (PK) and pharmacodynamic (PD) analyses were conducted to determine the cumulative fraction of response (CFR) for 100 mg twice-daily (BID) and 200 mg once-daily (QD) delamanid in patients with multidrug-resistant tuberculosis (MDR-TB), using a pharmacodynamic target (PDT) that achieves 80% of maximum efficacy. First, in the mouse model of chronic TB, the PK/PD index for delamanid efficacy was determined to be area under...

    Suresh Mallikaarjun, Moti L. Chapagain, Tomohiro Sasaki, Norimitsu Hariguchi, Devyani Deshpande, Shashikant Srivastava, Alexander Berg, Kuniko Hirota, Yusuke Inoue, Makoto Matsumoto, Jeffrey Hafkin, Lawrence Geiter, Xiaofeng Wang, Tawanda Gumbo, Yongge Liu
  • Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia
    Pharmacology
    Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia

    Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae. This agent is being developed for a range of serious hospital infections. An understanding of the extent of partitioning of β-lactam–β-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime...

    Shampa Das, Richard Fitzgerald, Asad Ullah, Marcin Bula, Andrea M. Collins, Elena Mitsi, Jesus Reine, Helen Hill, Jamie Rylance, Daniela M. Ferreira, Karen Tripp, Andrea Bertasini, Samantha Franzoni, Mameli Massimiliano, Omar Lahlou, Paola Motta, Philip Barth, Patrick Velicitat, Philipp Knechtle, William Hope
  • Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis
    Pharmacology
    Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis

    Isavuconazole is the newest triazole antifungal, and it displays a favorable pharmacokinetic and safety profile. Less is known about its long-term use in immunocompetent hosts. We performed a retrospective service evaluation of isavuconazole therapeutic drug monitoring in patients with chronic pulmonary aspergillosis. Adverse events (AEs) and dose adjustments made during routine clinical practice were recorded, and AEs were classified...

    Chris Kosmidis, Akan Otu, Caroline B. Moore, Malcolm D. Richardson, Riina Rautemaa-Richardson
  • First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span>
    Pharmacology
    First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus

    Mycobacterium abscessus causes serious infections that often require over 18 months of antibiotic combination therapy. There is no standard regimen for the treatment of M. abscessus infections, and the multitude of combinations that have been used clinically have had low success rates and high rates...

    Alaa R. M. Sayed, Nirav R. Shah, Kari B. Basso, Manasi Kamat, Yuanyuan Jiao, Bartolome Moya, Dhruvitkumar S. Sutaria, Yinzhi Lang, Xun Tao, Weiguo Liu, Eunjeong Shin, Jieqiang Zhou, Carolin Werkman, Arnold Louie, George L. Drusano, Jürgen B. Bulitta

Letters to the Editor

  • Risk of Serotonin Syndrome with Isoniazid
    Letter to the Editor
    Risk of Serotonin Syndrome with Isoniazid
    Michael E. O’Brien, Ronak G. Gandhi, Camille N. Kotton, Meagan L. Adamsick
  • <em>In Vitro</em> Susceptibility of <span class="named-content genus-species" id="named-content-1">Nocardia farcinica</span> to the Antimycobacterial Drug Clofazimine
    Letter to the Editor
    In Vitro Susceptibility of Nocardia farcinica to the Antimycobacterial Drug Clofazimine
    Ka Lip Chew, Sophie Octavia, Siang Fei Yeoh, Jeanette W. P. Teo
  • First Report of Multidrug-Resistant Carbapenemase-Producing Bacteria Coharboring <em>mcr-9</em> Associated with Respiratory Disease Complex in Pets: Potential of Animal-Human Transmission
    Letter to the Editor
    First Report of Multidrug-Resistant Carbapenemase-Producing Bacteria Coharboring mcr-9 Associated with Respiratory Disease Complex in Pets: Potential of Animal-Human Transmission
    Hazim O. Khalifa, Atef F. Oreiby, Amer Ali Abd El-Hafeez, Takashi Okanda, Anwaral Haque, Kazi S. Anwar, Masaki Tanaka, Keisuke Miyako, Shoji Tsuji, Yasuyuki Kato, Tetsuya Matsumoto
  • Improbable Results of Urine Isolate Antimicrobial Susceptibility Testing
    Letter to the Editor
    Improbable Results of Urine Isolate Antimicrobial Susceptibility Testing
    Paul H. Edelstein, Romney M. Humphries
  • Reply to Edelstein and Humphries, “Improbable Results of Urine Isolate Antimicrobial Susceptibility Testing”
    Letter to the Editor
    Reply to Edelstein and Humphries, “Improbable Results of Urine Isolate Antimicrobial Susceptibility Testing”
    Marya D. Zilberberg, Brian H. Nathanson, Kate Sulham, Andrew F. Shorr

Erratum

  • Free
    Erratum for Vimberg et al., “Ribosome-Mediated Attenuation of <em>vga</em>(A) Expression Is Shaped by the Antibiotic Resistance Specificity of Vga(A) Protein Variants”
    Erratum
    Erratum for Vimberg et al., “Ribosome-Mediated Attenuation of vga(A) Expression Is Shaped by the Antibiotic Resistance Specificity of Vga(A) Protein Variants”
    Vladimir Vimberg, Jorunn Pauline Cavanagh, Michaela Novotna, Jakub Lenart, Bich Nguyen Thi Ngoc, Jana Vesela, Maria Pain, Marketa Koberska, Gabriela Balikova Novotna

Author Correction

  • Free
    Correction for Kovacs et al., “An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline”
    Author Correction
    Correction for Kovacs et al., “An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline”
    Steven J. Kovacs, Lillian Ting, Jens Praestgaard, Gangadhar Sunkara, Haiying Sun, Daniel S. Stein, S. Ken Tanaka, Stephen Villano

Masthead

  • Free
    Editorial Board
    Masthead
    Editorial Board
Previous
Back to top

Antimicrobial Agents and Chemotherapy: 65 (1)

In This Issue

volume 65, issue 1
  • Table of Contents (PDF)
Sign up for alerts

Jump to

  • Perspective
  • Meeting Review
  • Challenging Clinical Case in Antimicrobial Resistance
  • Chemistry; Biosynthesis
  • Mechanisms of Action: Physiological Effects
  • Mechanisms of Resistance
  • Susceptibility
  • Analytical Procedures
  • Antiviral Agents
  • Epidemiology and Surveillance
  • Experimental Therapeutics
  • Clinical Therapeutics
  • Pharmacology
  • Letters to the Editor
  • Erratum
  • Author Correction
  • Masthead
  • Most Read
  • Most Cited
Loading
  • Mechanism-of-Action Classification of Antibiotics by Global Transcriptome Profiling
  • Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions
  • New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
  • Updated Approaches against SARS-CoV-2
More...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596